Plasma tissue factor pathway inhibitor and tissue factor antigen levels after administration of heparin in patients with angina pectoris

Thromb Res. 1999 Jan 1;93(1):17-25. doi: 10.1016/s0049-3848(98)00147-9.

Abstract

The hypercoagulability is associated with expression of tissue factor in patients with angina. Tissue factor pathway inhibitor regulates the extrinsic coagulation pathway mediated by tissue factor. Plasma samples were obtained from 14 patients with angina pectoris and 9 with chest pain syndrome before and 5, 30, 60, and 120 minutes after administration of heparin (50 IU/kg). The tissue factor and prothrombin fragment 1+2 levels before administration were elevated in patients with angina pectoris and were reduced to the levels of chest pain syndrome after the administration. The free tissue factor pathway inhibitor levels after the administration were higher in patients with angina pectoris than in patients with chest pain syndrome. Plasma tissue factor pathway inhibitor levels correlated positively with plasma tissue factor and prothrombin fragment 1+2 levels. We showed that plasma-free TFPI levels after administration of heparin, which may indicate endothelial cell associated TFPI levels, increased in patients with angina pectoris compared with patients with chest pain syndrome. Increased endothelial cell associated TFPI was associated with hypercoagulability in patients with angina pectoris. These may help to explain the reduction in thrombotic risk associated with the use of heparin.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angina Pectoris / blood
  • Angina Pectoris / drug therapy*
  • Angina Pectoris / immunology
  • Anticoagulants / blood
  • Anticoagulants / therapeutic use*
  • Antigens / blood*
  • Female
  • Heparin / blood
  • Heparin / therapeutic use*
  • Humans
  • Linear Models
  • Lipoproteins / blood*
  • Male
  • Middle Aged
  • Thromboplastin / immunology*

Substances

  • Anticoagulants
  • Antigens
  • Lipoproteins
  • lipoprotein-associated coagulation inhibitor
  • Heparin
  • Thromboplastin